C1S and hereditary angioedema: Recombinant or plasma-derived C1-esterase inhibitor is currently approved for the routine prophylaxis of hereditary angioedema by blocking the classical and lectin pathways of complement activation, as well as proteases of the fibrinolytic, clotting and kinin pathways45.